Biocon Ltd

Biocon Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Biocon Ltd

₹ 419 1.90%
17 Nov 2:44 p.m.
biocon.com BSE: 532523 NSE: BIOCON
About

Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)

Key Points

Business Segments
1) Biosimilars (58% in FY25 vs 50% in FY23): [1] [2] Biocon Biologics develops and markets a range of 20 biosimilars including insulins, monoclonal antibodies, and conjugated recombinant proteins across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. [3] It is one of the top 5 global players in biosimilars and among the top 3 in insulins. It ranks in the top 15 companies worldwide for biomanufacturing capacity and has a presence in 120+ countries, including the U.S., Europe, and emerging markets. Its product portfolio includes 10 approved biosimilars and 10 under development. [4]

The segment revenue grew by 2% YoY in FY25, driven by market share gains in the U.S. and key tender wins in the Emerging Markets. [5]

Website BSE NSE
  • Market Cap ₹ 55,992 Cr.
  • Current Price ₹ 419
  • High / Low ₹ 423 / 291
  • Stock P/E 698
  • Book Value ₹ 120
  • Dividend Yield 0.12 %
  • ROCE 2.09 %
  • ROE 0.40 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 22.2%
  • Company's working capital requirements have reduced from 142 days to 29.8 days

Cons

  • Stock is trading at 3.49 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 2.44% over past five years.
  • Company has a low return on equity of 0.43% over last 3 years.
  • Earnings include an other income of Rs.930 Cr.
  • Promoter holding has decreased over last 3 years: -6.19%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
490 555 507 513 519 563 533 511 525 563 644 537 583
462 518 551 441 452 492 480 466 488 532 582 516 530
Operating Profit 28 37 -44 72 67 71 52 45 38 31 62 21 53
OPM % 6% 7% -9% 14% 13% 13% 10% 9% 7% 6% 10% 4% 9%
1,108 60 1,918 56 64 48 39 42 74 672 63 61 134
Interest 0 21 48 48 55 56 40 55 60 65 57 56 67
Depreciation 30 29 29 30 31 31 30 30 30 34 33 33 34
Profit before tax 1,106 46 1,796 50 46 33 22 1 21 604 35 -8 86
Tax % 11% 24% -1% 6% 25% 27% 36% 18% 85% 3% 39% 9% 17%
988 35 1,811 47 35 24 14 1 3 584 21 -8 71
EPS in Rs 8.23 0.29 15.08 0.39 0.29 0.20 0.12 0.01 0.03 4.86 0.18 -0.06 0.53
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
2,202 2,242 2,302 2,588 2,419 1,786 1,988 2,028 1,738 1,993 2,127 2,243 2,327
1,729 1,812 1,880 1,996 2,101 1,575 1,702 1,716 1,677 1,969 1,864 2,066 2,160
Operating Profit 473 430 422 592 318 210 286 312 61 24 264 177 167
OPM % 21% 19% 18% 23% 13% 12% 14% 15% 4% 1% 12% 8% 7%
61 127 279 99 125 422 366 150 187 3,134 206 848 930
Interest 1 1 2 4 1 3 1 0 0 70 199 237 245
Depreciation 124 128 140 151 136 92 98 104 108 117 121 128 134
Profit before tax 409 428 559 536 306 537 553 359 140 2,971 150 661 717
Tax % 21% 16% 34% 3% 22% 8% 20% 22% 38% 4% 21% 8%
324 361 369 519 238 493 441 280 86 2,848 119 609 668
EPS in Rs 2.70 3.01 3.07 4.33 1.99 4.11 3.67 2.34 0.72 23.72 0.99 5.07 5.51
Dividend Payout % 31% 28% 27% 12% 25% 12% 0% 0% 70% 6% 50% 10%
Compounded Sales Growth
10 Years: 0%
5 Years: 2%
3 Years: 9%
TTM: 9%
Compounded Profit Growth
10 Years: -19%
5 Years: -32%
3 Years: -19%
TTM: 91%
Stock Price CAGR
10 Years: 18%
5 Years: -1%
3 Years: 13%
1 Year: 22%
Return on Equity
10 Years: 3%
5 Years: 1%
3 Years: 0%
Last Year: 0%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 100 100 100 100 300 300 600 600 600 600 600 600 668
Reserves 2,318 2,484 5,897 6,441 6,439 6,815 6,937 7,307 7,493 10,316 10,312 10,924 15,315
121 82 370 134 133 71 4 2 77 1,301 2,043 2,876 2,543
679 667 732 794 855 1,054 770 665 699 813 813 1,221 1,295
Total Liabilities 3,218 3,333 7,098 7,469 7,727 8,240 8,311 8,574 8,869 13,030 13,768 15,621 19,821
949 914 894 938 903 1,101 793 798 870 961 958 1,114 1,080
CWIP 102 58 172 241 318 254 152 179 285 344 560 701 822
Investments 493 165 3,853 3,888 4,199 4,093 4,953 5,413 5,280 9,271 9,318 11,383 14,133
1,674 2,196 2,179 2,402 2,307 2,792 2,413 2,184 2,434 2,454 2,932 2,424 3,787
Total Assets 3,218 3,333 7,098 7,469 7,727 8,240 8,311 8,574 8,869 13,030 13,768 15,621 19,821

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
186 125 208 186 355 110 387 478 48 219 -123 624
51 145 -313 104 -553 315 -189 -628 -302 -1,173 -295 -992
-187 -158 73 -238 -55 -208 -129 28 112 1,039 344 495
Net Cash Flow 50 112 -32 52 -252 217 69 -122 -142 86 -74 127

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 82 90 80 113 112 184 105 106 147 121 180 135
Inventory Days 131 148 187 190 195 371 236 197 245 208 260 296
Days Payable 99 109 146 159 202 298 230 170 172 169 175 288
Cash Conversion Cycle 115 129 121 144 105 257 111 133 220 159 265 143
Working Capital Days 52 76 42 108 87 214 154 122 181 151 244 30
ROCE % 17% 17% 10% 8% 4% 5% 5% 5% 2% 2% 3% 2%

Shareholding Pattern

Numbers in percentages

1 Recently
Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 54.45% 54.45%
14.42% 10.20% 9.52% 7.97% 6.55% 5.63% 5.90% 5.93% 5.66% 5.67% 6.04% 6.61%
8.63% 11.89% 12.59% 14.08% 14.51% 13.69% 14.29% 14.44% 15.36% 15.73% 22.83% 22.06%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03%
15.74% 16.70% 16.77% 16.92% 17.96% 19.74% 18.90% 18.74% 18.11% 17.77% 16.51% 16.70%
0.58% 0.55% 0.49% 0.39% 0.33% 0.32% 0.28% 0.25% 0.22% 0.21% 0.18% 0.14%
No. of Shareholders 3,91,3824,11,0864,12,4414,15,0464,34,3394,70,2614,43,5134,39,5034,27,7054,24,2974,28,1314,13,191

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls